Product Description
Mechanisms of Action: TLR4 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Injection
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Takeda
Company Location: Asia Pacific
Company Founding Year: 1781
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Acute-On-Chronic Liver Failure|End Stage Liver Disease|Hepatitis, Alcoholic|Hepatitis, Chronic|Liver Cirrhosis, Alcoholic|Liver Failure, Acute
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06890039 |
A-TANGO | P2 |
Not yet recruiting |
Hepatitis, Alcoholic|Liver Cirrhosis, Alcoholic|Acute-On-Chronic Liver Failure|End Stage Liver Disease|Hepatitis, Chronic|Liver Failure, Acute |
2026-02-28 |
12% |
2025-03-22 |
Primary Endpoints|Treatments |